Overview

A Study of Long-Term Safety and Efficacy of Lanadelumab for Prevention of Acute Attacks of Non-histaminergic Angioedema With Normal C1-Inhibitor

Status:
Recruiting

Trial end date:
2023-08-30

Target enrollment:

Participant gender:

Summary

The purpose of this study is to evaluate the long-term safety and efficacy of repeated subcutaneous (SC) administration of lanadelumab in adolescents and adults with non-histaminergic angioedema with normal C1-inhibitor who completed study SHP643-303 (NCT04206605).

Phase:

Phase 3

Details

Lead Sponsor:

Shire

Collaborator:

Takeda Development Center Americas, Inc.